Other OTC - Delayed Quote USD

CARsgen Therapeutics Holdings Limited (CRTHF)

1.6700

0.0000

(0.00%)

At close: December 4 at 9:31 AM EST

Key Events

Advanced Chart

Loading Chart for CRTHF

9/21 12:03 PM

DELL

Previous Close 1.6700
Open 1.6700
Bid --
Ask --
Day's Range 1.6700 - 1.6700
52 Week Range 1.6700 - 1.8600
Volume 100
Avg. Volume 0
Market Cap (intraday) 961.319M
Beta (5Y Monthly) 0.42
PE Ratio (TTM) --
EPS (TTM) -0.2300
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.

www.carsgen.com

516

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

CARsgen Announced 2023 Annual Results

$NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma$

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

$CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia$